

Friday Satellite Symposia

Preceding the 64th ASH Annual Meeting and Exposition

An illustration of a person with dark hair, wearing a dark shirt, with their back to the viewer. They have several red, circular skin lesions on their upper back and shoulder. The background is a light purple circle on a darker purple field.

Multidisciplinary Management of **BPDCN**: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy

IN-PERSON + LIVE STREAMING SATELLITE SYMPOSIUM

FRIDAY, DECEMBER 9, 2022

3:00 PM – 5:30 PM CST

PROGRAM CHAIR

Naveen Pemmaraju, MD

For more information, visit us at...

gotoper.com



STAY CONNECTED! Follow us @GoToPER and share your thoughts by using #gotoPER.

Dear Colleague:

On behalf of Physicians' Education Resource®, LLC (PER®), we would like to welcome you and thank you for choosing to attend **Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy**.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a clinically aggressive hematological malignancy derived from the precursors of plasmacytoid dendritic cells. A greater understanding of BPDCN's unique clinical presentation, clinical course, and disease biology led to reclassification of this disease as a myeloid neoplasm. However, early recognition of BPDCN has been challenging because its clinical features can be heterogeneous and overlap with other hematologic malignancies. Outcomes for patients with BPDCN are historically poor, but improved understanding of disease pathology has led to increased treatment options and standardization. This hybrid satellite symposium, held adjunct to the American Society of Hematology Annual Meeting, will include informative didactic sections and engaging case-based multidisciplinary faculty discussion designed to provide participants the opportunity to reflect on the disease burden and unmet needs for patients, review important safety and efficacy data for recently approved and emerging therapies for BPDCN, and identify strategies to integrate novel therapies into treatment plans.

In working together with PER®, we strive to make this activity, along with all PER® accredited continuing education (CE) activities, both useful and impactful for health care professionals like you who are involved with the care of patients with BPDCN.

If there is anything additional that you need, if you experience an issue, or if you have an idea for a future activity that would help you in the care of your patients, please let us know.

We could not have our accredited CE activities without you, and we appreciate your commitment to learning about the latest advancements in the treatment of cancer. Let's work together to make this an educational experience that will make a positive difference for our patients!

We hope you enjoy your experience at this first-class PER® symposium and that you can attend another PER® accredited CE activity soon.

Regards,

Naveen Pemmaraju, MD

Associate Professor, Department of Leukemia
Director, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Program
The University of Texas MD Anderson Cancer Center
Houston, TX

Jim Palatine, RPh, MBA

President
Physicians' Education Resource®, LLC
Cranbury, NJ
jpalatine@mjhlifesciences.com

AGENDA

2:15 PM	Registration and Lunch	
3:00 PM	Welcome and Introductions	Naveen Pemmaraju, MD
3:05 PM	Optimizing Diagnostic Practices For BPDCN: A Clinicopathologic Perspective	Andrew A. Lane, MD, PhD
3:30 PM	Panel Discussion	Moderated by Naveen Pemmaraju, MD
3:40 PM	Overview Of BPDCN And Current Treatment Options: Chemotherapy, Transplant, And CD123 Targeted Therapy	Naveen Pemmaraju, MD
4:10 PM	Panel Discussion	Moderated by Naveen Pemmaraju, MD
4:20 PM	Future Directions for BPDCN Treatment: What Is Next?	Muzaffar H. Qazilbash, MD
4:40 PM	Panel Discussion	Moderated by Naveen Pemmaraju, MD
4:50 PM	Scientific And Translational Perspectives On BPDCN: Potential Applications for Other Hematological Malignancies	Monica L. Guzman, PhD
5:05 PM	Panel Discussion	Moderated by Naveen Pemmaraju, MD
5:10 PM	Closing Remarks	Naveen Pemmaraju, MD
5:30 PM	Adjourn	

Upcoming PER® Conferences

2022

Inaugural International Congress Pediatric Oncology

December 16

2023

The 1st Annual Hawaii Lung: A Multidisciplinary Case-Based Conference™

Honolulu, HI

January 21

20th Annual Winter Lung Conference®

Hollywood, FL

February 3-5

19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

Dallas, TX

February 4

27th Annual International Congress on Hematologic Malignancies®

Miami Beach, FL

February 23-26

40th Annual Miami Breast Cancer Conference®

Miami Beach, FL

March 2-5

NYGU™ 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

New York, NY

March 10-11

8th Annual School of Gastrointestinal Oncology®

Orlando, FL

May 6

7th Annual International Congress on Oncology & Pathology™: Towards Harmonization of Pathology and Oncology Standards

May 6

14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies

May 13

22nd Annual International Congress on the Future of Breast Cancer® East

New York, NY

July 15-16

24th Annual International Lung Cancer Congress®

Huntington Beach, CA

July 27-29

22nd Annual International Congress on the Future of Breast Cancer® West

San Diego, CA

July 28-29

20th Annual Meeting of the International Society of Gastrointestinal Oncology®

Tempe, AZ

October 13-14

21st Annual School of Breast Oncology®

Atlanta, GA

November 2-4

41st Annual CFS®: Innovative Cancer Therapy for Tomorrow®

New York, NY

November 8-10

18th Annual New York Lung Cancers Symposium®

New York, NY

November 11



Virtual Conference



In-Person + Virtual Conference



In-Person Conference

Target Audience

This educational activity is directed toward medical oncologists, hematologic oncologists, hematologists, pathologists, nurses, and other health care professionals involved in the treatment of BPDCN.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

- Explain the clinical presentation, cytogenetics, and pathophysiological mechanisms of BPDCN
- Apply criteria for the timely diagnosis of BPDCN, including methods for differential diagnosis, through optimization of multidisciplinary collaboration
- Assess the clinical profiles of current and emerging CD123-targeted therapeutic approaches that have been investigated for the treatment of patients with BPDCN
- Incorporate updated guidelines and pivotal trial data on current/emerging agents targeting CD123 into personalized treatment plans for patients with BPDCN

Slides/e-Syllabus

Final slides will be uploaded to the e-syllabus on the PER® website by 12 PM EST on Monday, December 12, 2022. To access these materials, please visit <https://www.gotoper.com/bpdcn1222iss-esyl>.

How to Request Credit

To complete the online evaluation and receive a certificate of credit or participation, please visit

<https://www.gotoper.com/bpdcn1222iss-eval>.

The online evaluation and request for credit will be available immediately following the program and will remain available until January 23, 2023.

Accreditation/Designation of Credit

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 2.5 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement of Educational Grant Support

This activity is supported by educational grants from ImmunoGen, Inc., Menarini-Stemline, and Mustang Bio, Inc.

Thank you for attending **Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy!**

To register for upcoming accredited CE live activities or to view our online accredited CE activities, please visit www.gotoper.com.

We appreciate your attendance and look forward to seeing you at future PER® accredited CE activities.



Faculty, Staff, and Planners' Disclosures

The following individuals have no relevant financial relationships with ineligible companies to disclose: the staff of Physicians' Education Resource®, LLC.

The following individuals have relevant financial relationships with ineligible companies to disclose*:

Faculty	Grant/Research Support	Consultant	Speakers' Bureau	Other
Monica L. Guzman, PhD	BridgeMedicines	BridgeMedicines, Janssen	SeqRx	
Andrew A. Lane, MD, PhD	Stemline Therapeutics, AbbVie	Qiagen, Adaptimmune, Cimeio		
Naveen Pemmaraju, MD		Protagonist Therapeutics, Cimeio Therapeutics, Immunogen, AbbVie, Astellas Pharma US, Inc., CTI BioPharma, PharmaEssentia, Patient Power, Stemline Therapeutics, Inc., Novartis, Incyte, Bristol-Myers Squibb, ClearView Healthcare Partners, Aptitude Health, Blueprint Medicines		Scientific Advisory Board or Preceptorship: Incyte, Menarini Group, Pacylex, Blueprint Medicines, CTI BioPharma, Cancer.Net, CareDx, EUSA Pharma, Inc., Novartis, PharmaEssentia, Protagonist Therapeutics, Dava Oncology, AbbVie, Curio Science LLC, Aplastic Anemia & MDS International Foundation Postgraduate Institute for Medicine, Neopharm, Stemline Therapeutics, Inc.
Muzaffar H. Qazilbash, MD	Janssen, Angiocrine, NexImmune, Bioline			

**Information accurate at time of printing*

PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing medical and/or nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

Physician Payments Sunshine Act

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.

Program Chair



Naveen Pemmaraju, MD

Associate Professor, Department of Leukemia
Director, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Program
The University of Texas MD Anderson Cancer Center
Houston, TX

Naveen Pemmaraju, MD, is an associate professor and the director of the Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Program at The University of Texas MD Anderson Cancer Center. After completing his Internal Medicine training at Johns Hopkins, in the Osler Medical Program, Dr. Pemmaraju subsequently completed both hematology and oncology training at MD Anderson Cancer Center (MDACC). He was selected as a chief fellow in my second year of training and obtained ABIM board certification in Internal Medicine, Hematology and Oncology, and continued his career at MDACC as an assistant professor in the department of Leukemia. He has an active clinical schedule during which he see patients: 2 full days of clinic per week, and 2 months of inpatient service per year. Dr. Pemmaraju has fellow teaching responsibilities as a Leukemia hematology/oncology course director and was the sole recipient of the MDACC Gerald P. Bodey Award for Excellence in Education in 2020. Dr. Pemmaraju's clinical and translational research work has been focused on improving outcomes and developing novel therapies for patients with rare myeloid malignancies, including for adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Myeloproliferative Neoplasms (MPN) and Acute Myeloid Leukemia (AML).

Faculty



Monica L. Guzman, PhD

Associate Professor of Pharmacology in Medicine
Weill Cornell Medical College
New York, NY

Monica L. Guzman, PhD, is an associate professor of Pharmacology in Medicine, in the Division of Hematology and Medical Oncology at Weill Cornell Medical College. Dr. Guzman leads a research program focused on the development of therapeutic strategies for targeting leukemic stem cells. Her laboratory utilizes and develops flow cytometry, NGS approaches to evaluate LSCs and assess MRD. In close collaboration with physicians and industry, her research has resulted in the translation of laboratory findings into clinical trials.

She has authored or co-authored more than 50 papers in the field and has received funding from The Leukemia & Lymphoma Society, NIH, V Foundation, and the Lauri Strauss Leukemia Foundation, among other organizations. Dr. Guzman was the recipient of the NIH Director's Innovator Award and the V Foundation Scholar Award, both in 2010. In 2020 she was listed in 100 inspiring Hispanic/Latinx scientists in America.

Faculty

**Andrew A. Lane, MD, PhD**

Associate Professor, Medicine
 Harvard Medical School
 Associate Professor, Medical Oncology
 Dana-Farber Cancer Institute
 Boston, MA

Andrew A. Lane, MD, PhD, is co-leader of the Dana-Farber/Harvard Cancer Center Leukemia Program and director of the BPDCCN Center at the Dana-Farber Cancer Institute. He is a physician in the Adult Leukemia Program and a laboratory investigator in the Department of Medical Oncology at DFCI, and an Associate Professor of Medicine at Harvard Medical School.

**Muzaffar H. Qazilbash, MD**

Professor of Medicine
 Director, Myeloma Transplantation and Cellular Therapy
 Department of Stem Cell Transplantation and Cellular Therapy
 The University of Texas MD Anderson Cancer Center
 Houston, TX

Muzaffar H. Qazilbash, MD, is a Professor in the Department of Stem Cell Transplantation and Cellular Therapy at UT MD Anderson Cancer Center, which he joined in October 2002. He completed his hematology-oncology fellowship at the National Institutes of Health (NIH) in Bethesda, Maryland. Dr. Qazilbash's clinical and research work has been focused on improving the outcomes of stem cell transplantation and cellular therapy for patients with multiple myeloma and related disorders.

As Director of Myeloma Transplantation and Cellular Therapy in the Department of Stem Cell Transplantation and Cellular Therapy, Dr. Qazilbash leads one of the largest myeloma transplant programs in the country. He has led several clinical trials for myeloma and related disorders, funded by the NIH and various philanthropic organizations. He has served as the Principal Investigator for the idiotype vaccine and cellular therapy studies (2004-0660, 2010- 0710) for myeloma, funded by the National Cancer Institute (SPORE) and the Leukemia Lymphoma Society (SCOR). He also led the PR1 vaccine trial (DM97-325), an NCI-sponsored study (# T98-0017) that received national recognition due to its novel approach and encouraging results.


Dr. Qazilbash has authored or co-authored more than 220 articles in peer-reviewed medical journals and serves in leadership positions at various institutional and extramural committees. He has been invited to present his work at many national and international symposia. He also leads the Clinical Research Committee within the Department of Stem Cell Transplantation, and serves as a member of the Advisory Council of Clinical Research Leaders at the MD Anderson Cancer Center.

Did you miss one of our sessions?


Check out the On-Demand Video Updates
from the Annual Hematology Meeting

—*Rapid Archive from*→ **NEW ORLEANS**


Archives will be available on December 10th



**Optimized use of MRD in
Hematologic Malignancies**




State-of-the-Art CMV Care




**Emerging Treatments for
Anemia in CKD**



**Holistic Approaches in
Sickle Cell Disease Treatment**




**Diagnosis and Treatment of
Hemolytic Anemias**




**Optimized Treatments for
ALL in Adolescents and Adults**




**Multidisciplinary Management
of BPDCN**




**Maximizing Clinical Practice
for Hodgkin Lymphoma**



**State-of-the-Art Care for
MF and PV**




**Exploring Gene Therapy in
Hemophilia B**



**Diagnosing Uncommon
Hematologic Disorders**



**Novel Therapies to Prevent
and Treat GvHD**



**Novel Treatments for Indolent
and Aggressive B-Cell Lymphomas**



**Treating Transfusion-Related
Iron Overload**



Scan the QR code below
or visit gotoper.com/ASH22
to view the symposia archive.

 **PER**[®]
Physicians'
Education
Resource, LLC
gotoper.com